With or Without CPAP, a Daily Weight-Loss Pill Eased Sleep Apnea

CATEGORY: SLEEP & RECOVERY

Some people with sleep apnea wear a CPAP mask every night and wish they didn’t have to. Others quit the machine, or never start. For both groups, a year on the weight-loss pill orforglipron cut breathing interruptions by about 12 to 13 more events per hour than a placebo did, in two trials covering 712 adults with obesity and moderate-to-severe apnea.¹ Apnea severity fell 26% to 35% on the pill. On placebo, it fell 3% to 5%.

Starting From Nearly a Pause a Minute

Both ATTAIN-OSA trials ran for 52 weeks at 66 clinics in nine countries. One enrolled people who weren’t using a breathing machine. The other enrolled regular CPAP users, who paused the machine for a week before each overnight sleep test so the measurements reflected the pill, not the mask. Every participant carried extra weight, didn’t have diabetes, and started with an apnea-hypopnea index of at least 15. That index counts how often breathing stops or goes shallow each hour of sleep. The average here was around 50 to 58, close to once a minute, all night. A computer decided who got orforglipron and who got an identical dummy pill, and nobody involved knew which was which until the year ended. Everyone also received counseling on food and activity.

Weight Fell by a Tenth, and Breathing Followed

Orforglipron is a daily tablet in the GLP-1 family, the hormone-mimicking drugs behind the weight-loss shots. People taking it lost about 10% of their body weight over the year, against roughly 1% to 2% on placebo. Their sleep improved with it. In the no-machine trial, interruptions dropped by 17.8 events per hour versus 4.5 on placebo. Among CPAP users, the figures were 17.3 versus 5.3. By year’s end, 28% of pill takers in the first trial and 19% in the second had lowered their levels enough to be considered mild or resolved apnea. Placebo got 13% and 9% there. Not everything moved: a questionnaire score of daytime, sleep-related functioning improved in both groups about equally, with no clear edge for the drug.

On Pharmacy Shelves, Though Not Yet for Apnea

The FDA approved orforglipron, marketed as Foundayo, in April 2026 for managing chronic weight. It isn’t approved for sleep apnea itself; that decision would come later. An injected relative, tirzepatide, already holds an apnea approval, and a trial of another weekly shot, retatrutide, found the same pattern of fewer interruptions as weight came off.² The familiar trade-off applies here too. Stomach trouble was the most common complaint, with nausea in roughly a third of pill takers, and about one in eight people in the no-machine trial stopped because of side effects. Eli Lilly, the pill’s maker, funded both trials. What a year of easier breathing does to hearts, blood pressure, or daytime alertness over the long run is a question these trials weren’t built to answer.

Key Takeaways

• A daily orforglipron pill lowered sleep apnea severity by about 13 more events per hour than placebo over a year, whether or not people used CPAP.
• The drug’s weight loss, around a tenth of body weight, is the likely engine of the improvement, and a daytime-functioning score didn’t clearly improve.
• Nausea and other stomach side effects were common, and the pill is approved for weight management but not, so far, for sleep apnea.

References

1. Malhotra A, Gottlieb DJ, Woehrle H, et al. Orforglipron for Obstructive Sleep Apnea: Results From 2 Randomized Clinical Trials (ATTAIN-OSA). JAMA. 2026; DOI 10.1001/jama.2026.24080. link
2. Grunstein RR, Somers VK, Azarbarzin A, et al. Retatrutide Once Weekly for Treatment of Obstructive Sleep Apnea. N Engl J Med. 2026; DOI 10.1056/NEJMoa2611477. link